The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Asian Patients With Psoriasis Receive Shortest Visits With Dermatologists

August 3rd 2022, 3:00pm


Dermatologists spend less time face-to-face with Asian patients with psoriasis compared with patients of other races and ethnicities, despite Asian patients frequently experiencing more severe cases of psoriasis.

Dr Patrick Burnett Addresses Unmet Needs, Management Strategies in Psoriasis

July 30th 2022, 12:20pm


Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, speaks about disease manifestations, comorbidities, and other factors to consider in the management of psoriasis.

Psoriasis Associated With Higher Risk of Organ-Based Comorbidities

July 25th 2022, 8:51pm


According to the investigator, these findings further support psoriasis as a systemic inflammatory disease.

Dr Patrick Burnett Discusses Risk Factors for Adverse Behavioral Health, QOL in Psoriasis

July 23rd 2022, 4:50pm


Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discussed key factors associated with poor behavioral health issues and quality of life among patients with psoriasis.

Psoriasis, Psoriatic Arthritis Linked With Age, Earlier Birth Cohorts

July 21st 2022, 1:30pm


Despite incidence of psoriasis decreasing, older populations in Taiwan have a higher risk of developing psoriasis and psoriatic arthritis, according to a recent study.

Dr Patrick Burnett Reviews Patient Survey Findings on Unmet Needs in Psoriasis

July 14th 2022, 6:40pm


Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses findings of a recent survey exploring the emotional burden of plaque psoriasis and unmet needs related to current topical treatments.

Drug Survival of Psoriasis Biologics Associated With Efficacy, Safety Profile

July 6th 2022, 4:09pm


Drug survival rates of biologics in patients with psoriasis were shown to be associated with their effectiveness and safety profiles, in which incidence of psoriatic arthritis, nail involvement, and other factors were indicated as effect modifiers.

Mendelian Randomization Study Suggests Causal Relationship Between IBD, Psoriasis

July 2nd 2022, 1:15pm


A Mendelian randomization study found that there appears to be a causal relationship between inflammatory bowel disease (IBD) and psoriasis.

No Increased Risk of Severe COVID-19 Among Children With Psoriasis Using Biologics

July 1st 2022, 9:15pm


Researchers found no evidence of increased risk for severe COVID-19 among children receiving biologic therapies for their psoriasis.

PsA Linked With Higher Prevalence of Cardiovascular Events, Risk Factors

June 24th 2022, 7:20pm


Patients with psoriatic arthritis (PsA) exhibited a higher prevalence of cardiovascular risk factors and events vs the general population, including atherothrombotic disease.